These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 34252464

  • 1. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
    Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour TL, Lew CR, Zimmerman NM, Atiya B, Murage MJ.
    J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
    [Abstract] [Full Text] [Related]

  • 2. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ.
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
    Blauvelt A, Shi N, Burge R, Somani N, Ridenour TL, Zhu B, Atiya B, Lew CR, Zimmerman NM, Murage MJ.
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2133-2145. PubMed ID: 34652590
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
    Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ.
    Patient Prefer Adherence; 2020 Dec; 14():517-527. PubMed ID: 32210539
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
    Blauvelt A, Shi N, Murage M, Ridenour T, Lew C, Somani N, Zhu B, Zimmerman N, Kern S, Burge R.
    J Drugs Dermatol; 2022 Apr 01; 21(4):399-407. PubMed ID: 35389589
    [Abstract] [Full Text] [Related]

  • 6. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
    Blauvelt A, Burge R, Gallo G, Charbonneau B, Malatestinic W, Zhu B, Wan F, Lockshin B.
    Dermatol Ther (Heidelb); 2022 Mar 01; 12(3):701-714. PubMed ID: 35220545
    [Abstract] [Full Text] [Related]

  • 7. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
    Fitzgerald T, Zhdanava M, Pilon D, Shah A, Hilts A, Lefebvre P, Feldman SR.
    Dermatol Ther (Heidelb); 2023 Apr 01; 13(4):1053-1068. PubMed ID: 36929120
    [Abstract] [Full Text] [Related]

  • 8. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
    Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA.
    J Manag Care Spec Pharm; 2023 Jan 01; 29(1):24-35. PubMed ID: 36318701
    [Abstract] [Full Text] [Related]

  • 9. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice.
    Caldarola G, Mariani M, Pirro F, Nicolotti N, Burlando M, Calabrese L, Parodi A, Peris K, De Simone C.
    Expert Opin Biol Ther; 2021 Feb 01; 21(2):279-286. PubMed ID: 33170052
    [Abstract] [Full Text] [Related]

  • 10. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Rull EV, Llamas-Velasco M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A.
    Am J Clin Dermatol; 2022 Nov 01; 23(6):891-904. PubMed ID: 35976568
    [Abstract] [Full Text] [Related]

  • 11. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States.
    Zhdanava M, Fitzgerald T, Pilon D, Teneralli RE, Shah A, Diaz L, Lefebvre P, Feldman SR.
    J Dermatolog Treat; 2024 Dec 01; 35(1):2349658. PubMed ID: 38747375
    [Abstract] [Full Text] [Related]

  • 12. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
    Egeberg A, Bryld LE, Skov L.
    J Am Acad Dermatol; 2019 Jul 01; 81(1):173-178. PubMed ID: 30914343
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A.
    J Med Econ; 2018 Aug 01; 21(8):810-820. PubMed ID: 29873270
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
    Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E.
    Dermatol Ther; 2020 May 01; 33(3):e13313. PubMed ID: 32181962
    [Abstract] [Full Text] [Related]

  • 15. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases.
    Leonardi C, Zhu B, Malatestinic WN, Eastman WJ, Guo J, Murage MJ, Choong CK, Burge R, Blauvelt A.
    Adv Ther; 2022 Jul 01; 39(7):3214-3224. PubMed ID: 35570242
    [Abstract] [Full Text] [Related]

  • 16. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S, Solomon Cohen E, Amitay-Laish I, Hodak E, Pavlovsky L.
    Acta Derm Venereol; 2019 Jul 01; 99(9):769-773. PubMed ID: 31017250
    [Abstract] [Full Text] [Related]

  • 17. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A, Shi N, Murage MJ, Kern SA, Somani N, Burge R, Ridenour TL, Lew CR, Zimmerman NM, Zhu B.
    J Med Econ; 2022 Jul 01; 25(1):741-749. PubMed ID: 35615978
    [Abstract] [Full Text] [Related]

  • 18. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T, Schäkel K.
    J Dermatolog Treat; 2019 May 01; 30(3):216-220. PubMed ID: 30051725
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rapid and sustained resolution in generalized pustular psoriasis with IL-17A inhibitors required high adherence: a 96-week analysis in a real-life setting.
    Hu K, Liu Y, Liu Y, Jian L, Duan Y, Liu R, Zhang H, Chen J, Zhang M, Kuang Y.
    Int J Dermatol; 2024 Nov 01; 63(11):1551-1557. PubMed ID: 38632699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.